Biomarin Pharmaceutical Inc (BMRN)

Debt-to-equity ratio

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Long-term debt	US$ in thousands	593,605	593,095	592,586	1,084,990	1,084,010	1,083,020	1,082,030	1,081,050	1,080,060	1,079,080	1,078,090	1,077,110	1,076,130	1,075,140	1,074,160	1,073,200	486,713	486,238	843,616	839,165
Total stockholders’ equity	US$ in thousands	5,073,820	4,951,550	4,896,900	4,782,830	4,659,040	4,603,160	4,568,510	4,499,740	4,386,240	4,265,670	4,261,080	4,236,500	4,162,010	4,100,930	4,053,890	3,236,680	3,239,960	3,122,380	3,074,400	2,960,950
Debt-to-equity ratio		0.12	0.12	0.12	0.23	0.23	0.24	0.24	0.24	0.25	0.25	0.25	0.25	0.26	0.26	0.26	0.33	0.15	0.16	0.27	0.28

March 31, 2024 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $593,605K ÷ $5,073,820K
= 0.12

The debt-to-equity ratio of Biomarin Pharmaceutical Inc has shown some fluctuations over the past few quarters. From December 2019 to March 2020, the ratio increased from 0.16 to 0.33, indicating a significant rise in debt relative to equity. However, this trend reversed in the subsequent quarters, with the ratio gradually declining to 0.12 by December 2023.

The consistent decrease in the debt-to-equity ratio from June 2020 to December 2023 suggests that Biomarin Pharmaceutical Inc has been reducing its reliance on debt financing in relation to shareholder equity. This can be seen as a positive sign of financial stability and effective capital management.

Overall, the debt-to-equity ratio of Biomarin Pharmaceutical Inc has shown a favorable trend of decreasing over the analyzed period, indicating a potentially stronger financial position and lower financial risk for the company. However, continuous monitoring is essential to ensure the company's financial health and sustainability in the long term.